Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1/2 6Phase 1 5Phase 3 2Phase NA 1Phase 2/3 1

Status

Unknown 3Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 2Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Recurrence 2Solid Tumor 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma 1Hodgkin Disease 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × SHR-1701 × Clear all
NCT04624217 2024-01-11

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Completed
56 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04407741 2023-12-12

Phase â… /â…¡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Chinese PLA General Hospital

Phase 1/2 Unknown
100 enrolled
Lymphoid

Lymphoma

NCT05896046 2023-06-15

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Chinese PLA General Hospital

Phase 1/2 Recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05503888 2022-08-17

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Not yet recruiting
160 enrolled

Recurrence

NCT04679038 2022-01-26

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
222 enrolled
Other solid neoplasm

Solid Tumor

NCT05020925 2021-08-25

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡